CellaVision Past Earnings Performance
Past criteria checks 5/6
CellaVision has been growing earnings at an average annual rate of 8.4%, while the Medical Equipment industry saw earnings growing at 22.9% annually. Revenues have been growing at an average rate of 10.2% per year. CellaVision's return on equity is 19.6%, and it has net margins of 20.4%.
Key information
8.4%
Earnings growth rate
8.4%
EPS growth rate
| Medical Equipment Industry Growth | 6.2% |
| Revenue growth rate | 10.2% |
| Return on equity | 19.6% |
| Net Margin | 20.4% |
| Next Earnings Update | 06 Feb 2025 |
Recent past performance updates
Recent updates
Does CellaVision (STO:CEVI) Have A Healthy Balance Sheet?
Nov 20
CellaVision AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Oct 27CellaVision AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Jul 24Is CellaVision (STO:CEVI) A Risky Investment?
Jun 07Does CellaVision (STO:CEVI) Deserve A Spot On Your Watchlist?
May 22CellaVision (STO:CEVI) Is Due To Pay A Dividend Of SEK2.25
Apr 13CellaVision AB (publ)'s (STO:CEVI) Intrinsic Value Is Potentially 46% Above Its Share Price
Apr 09CellaVision (STO:CEVI) Will Pay A Dividend Of SEK2.25
Mar 28CellaVision's (STO:CEVI) Dividend Will Be SEK2.25
Mar 14CellaVision (STO:CEVI) Will Pay A Dividend Of SEK2.25
Feb 29After Leaping 28% CellaVision AB (publ) (STO:CEVI) Shares Are Not Flying Under The Radar
Feb 16CellaVision (STO:CEVI) Will Pay A Dividend Of SEK2.25
Feb 12Earnings Beat: CellaVision AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Feb 10CellaVision's (STO:CEVI) Returns On Capital Not Reflecting Well On The Business
Dec 13Is Now An Opportune Moment To Examine CellaVision AB (publ) (STO:CEVI)?
Sep 14Calculating The Intrinsic Value Of CellaVision AB (publ) (STO:CEVI)
Aug 22CellaVision (STO:CEVI) Is Reinvesting At Lower Rates Of Return
Jun 17CellaVision's (STO:CEVI) Upcoming Dividend Will Be Larger Than Last Year's
May 07Estimating The Fair Value Of CellaVision AB (publ) (STO:CEVI)
Apr 19CellaVision (STO:CEVI) Is Increasing Its Dividend To SEK2.25
Apr 05CellaVision (STO:CEVI) Is Paying Out A Larger Dividend Than Last Year
Mar 04CellaVision AB (publ) (STO:CEVI) Analysts Are More Bearish Than They Used To Be
Feb 11Is CellaVision (STO:CEVI) A Risky Investment?
Jan 13Is CellaVision AB (publ) (STO:CEVI) Potentially Undervalued?
Dec 13CellaVision (STO:CEVI) Seems To Use Debt Rather Sparingly
Sep 23CellaVision (STO:CEVI) May Have Issues Allocating Its Capital
Aug 16Calculating The Intrinsic Value Of CellaVision AB (publ) (STO:CEVI)
Aug 02We Ran A Stock Scan For Earnings Growth And CellaVision (STO:CEVI) Passed With Ease
Jun 27What Is CellaVision AB (publ)'s (STO:CEVI) Share Price Doing?
May 31Revenue & Expenses Breakdown
How CellaVision makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 737 | 150 | 219 | 86 |
| 30 Jun 24 | 726 | 145 | 217 | 83 |
| 31 Mar 24 | 708 | 141 | 213 | 84 |
| 31 Dec 23 | 677 | 130 | 213 | 83 |
| 30 Sep 23 | 629 | 112 | 202 | 83 |
| 30 Jun 23 | 602 | 97 | 196 | 91 |
| 31 Mar 23 | 616 | 99 | 196 | 91 |
| 31 Dec 22 | 639 | 118 | 191 | 89 |
| 30 Sep 22 | 651 | 126 | 194 | 86 |
| 30 Jun 22 | 642 | 142 | 186 | 72 |
| 31 Mar 22 | 594 | 135 | 174 | 67 |
| 31 Dec 21 | 566 | 125 | 165 | 64 |
| 30 Sep 21 | 532 | 114 | 160 | 61 |
| 30 Jun 21 | 488 | 101 | 150 | 54 |
| 31 Mar 21 | 471 | 98 | 147 | 52 |
| 31 Dec 20 | 471 | 89 | 152 | 51 |
| 30 Sep 20 | 490 | 85 | 159 | 54 |
| 30 Jun 20 | 498 | 89 | 165 | 59 |
| 31 Mar 20 | 492 | 92 | 163 | 60 |
| 31 Dec 19 | 462 | 99 | 150 | 56 |
| 30 Sep 19 | 423 | 104 | 135 | 53 |
| 30 Jun 19 | 412 | 104 | 131 | 48 |
| 31 Mar 19 | 391 | 97 | 124 | 43 |
| 31 Dec 18 | 365 | 89 | 120 | 39 |
| 30 Sep 18 | 330 | 76 | 114 | 33 |
| 30 Jun 18 | 307 | 67 | 109 | 30 |
| 31 Mar 18 | 294 | 63 | 106 | 27 |
| 31 Dec 17 | 309 | 70 | 106 | 27 |
| 30 Sep 17 | 306 | 70 | 101 | 28 |
| 30 Jun 17 | 313 | 78 | 97 | 28 |
| 31 Mar 17 | 300 | 75 | 92 | 30 |
| 31 Dec 16 | 265 | 60 | 86 | 29 |
| 30 Sep 16 | 254 | 57 | 85 | 29 |
| 30 Jun 16 | 260 | 66 | 82 | 27 |
| 31 Mar 16 | 246 | 55 | 82 | 28 |
| 31 Dec 15 | 239 | 53 | 82 | 27 |
| 30 Sep 15 | 250 | 49 | 84 | 29 |
| 30 Jun 15 | 223 | 30 | 82 | 28 |
| 31 Mar 15 | 226 | 34 | 83 | 25 |
| 31 Dec 14 | 217 | 31 | 80 | 23 |
| 30 Sep 14 | 209 | 33 | 73 | 19 |
| 30 Jun 14 | 207 | 36 | 70 | 17 |
| 31 Mar 14 | 189 | 26 | 67 | 18 |
| 31 Dec 13 | 180 | 19 | 66 | 21 |
Quality Earnings: CEVI has high quality earnings.
Growing Profit Margin: CEVI's current net profit margins (20.4%) are higher than last year (17.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CEVI's earnings have grown by 8.4% per year over the past 5 years.
Accelerating Growth: CEVI's earnings growth over the past year (33.9%) exceeds its 5-year average (8.4% per year).
Earnings vs Industry: CEVI earnings growth over the past year (33.9%) exceeded the Medical Equipment industry 31%.
Return on Equity
High ROE: CEVI's Return on Equity (19.6%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 18:39 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
CellaVision AB (publ) is covered by 10 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sten Gustafsson | ABG Sundal Collier |
| Bjorn Rydell | ABG Sundal Collier Sponsored |
| Carl-Oscar Bredengen | Berenberg |